Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer.
This study was aimed to identify the expression and the correlation of insulin-like growth factor-1 (IGF-1) system and their prognostic impacts in cervical cancer. Seventy-two patients with early-stage cervical cancer were eligible. We obtained the serum levels of total IGF-1 and IGF binding protein-3 (IGFBP-3) by enzyme-linked immunosorbent assay and the expression of IGF-1 receptor (IGF-1R) in cancerous tissue by immuno-fluorescent (IF) stains. The 5-year recurrence-free and overall survival rates were significantly lower (P=0.003 and P=0.01, respectively) among patients with high-grade expression of tissue IGF-1R, compared with those with low-grade expression. After adjustment for other factors, preoperative serum total IGF-1 or IGFBP-3 levels failed to predict cancer death and recurrence. High-grade expression of IGF-1R and elevated preoperative squamous cell carcinoma antigen level were independent predictors of both death and recurrence, and combination of both factors could further help identify the subgroup of patients at higher death risk. The IF staining indicates the colocalisation of IGF-1 and IGF-1R in the cancerous tissues, whereas the IGF-1R expression is not correlated with circulating levels of IGF-1 or IGFBP-3. In early-stage cervical cancer, IGF-1 system may have a paracrine or autocrine function and the adverse impacts on prognosis by IGF-1R overexpression are implicated.
Huang
Y-F
YF
Department of Obstetrics & Gynecology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Shen
M-R
MR
Hsu
K-F
KF
Cheng
Y-M
YM
Chou
C-Y
CY
D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000502:physiology*; D015999:Multivariate Analysis; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D015398:Signal Transduction; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000503:physiopathology*
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1
Acta Obstet Gynecol Scand. 2002 May;81(5):451-7
12027820
Carcinogenesis. 2007 May;28(5):947-56
17183068
Virology. 1991 Sep;184(1):9-13
1651607
Breast Cancer Res Treat. 2002 Jul;74(1):65-76
12150454
Endocr Relat Cancer. 2007 Mar;14(1):81-90
17395977
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):716-22
17416762
Semin Surg Oncol. 1999 Apr-May;16(3):203-11
10225296
J Cell Physiol. 2007 Mar;210(3):626-36
17133354
Endocr Rev. 1995 Feb;16(1):3-34
7758431
Clin Cancer Res. 2007 Jun 15;13(12):3611-6
17575225
Eur J Cancer. 2007 Sep;43(13):1895-904
17624760
Gynecol Oncol. 2006 Feb;100(2):389-96
16300820
Cancer Res. 2005 Nov 15;65(22):10123-7
16287993
Cancer. 1994 Nov 1;74(9):2497-501
7923006
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
10203281
Science. 1998 Jan 23;279(5350):563-6
9438850
J Clin Oncol. 2005 Mar 1;23(7):1455-62
15735121
Gynecol Oncol. 1997 Mar;64(3):418-24
9062143
Cancer Res. 1996 Apr 15;56(8):1761-5
8620490
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
Clin Cancer Res. 2003 Aug 15;9(9):3356-61
12960122
Biomedica. 2006 Jun;26(2):258-68
16925098
Br J Haematol. 2005 Jul;130(1):58-66
15982345
Obstet Gynecol. 1992 May;79(5 ( Pt 1)):675-82
1314359
Cancer Res. 1995 May 15;55(10):2007-11
7743492
Lancet. 2004 Apr 24;363(9418):1346-53
15110491
J Natl Cancer Inst. 1999 Jan 20;91(2):151-6
9923856
Oncology. 2004;67(3-4):225-30
15557783
Am J Clin Pathol. 2004 Dec;122(6):931-7
15539386
Int J Cancer. 2000 Dec 1;88(5):828-32
11072255
Gynecol Oncol. 2003 Dec;91(3):486-93
14675666
Carcinogenesis. 2006 May;27(5):962-71
16400188
Biosci Trends. 2007 Dec;1(3):128-33
20103882
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2181-5
8134369
J Biol Chem. 2004 Sep 17;279(38):40017-25
15262997
J Biol Chem. 1993 Jan 15;268(2):1087-94
7678247
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
10995803